Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
UnitedHealth Group Incorporated reports that its senior management team will meet with investors on January 12, 2026 and intends to reaffirm the company’s adjusted 2025 earnings per share expectations that were previously communicated on October 28, 2025. This indicates the company is currently standing by its earlier profit outlook for 2025.
The company also explains that its financial closing procedures for full-year 2025 are not yet complete, so actual results may change as closing activities, final adjustments, management review, and other developments occur. It cautions that final 2025 results could ultimately fall outside the previously discussed ranges, underscoring that this is a reaffirmation of expectations rather than a report of final earnings.
UnitedHealth Group director equity compensation reported
A Form 4 reports that director Paul R. Garcia received equity-based compensation from UnitedHealth Group Inc. (UNH) on 01/02/2026. The filing shows a grant of 168 deferred stock units at a price of $0, described as regular quarterly compensation for Board service. These deferred stock units are immediately vested but must be held until his Board service ends. The filing also shows a separate grant of 112 shares of common stock at $0, also as regular quarterly director compensation. Following these transactions, he beneficially owns UnitedHealth Group common stock directly and indirectly, including shares held through several trusts.
UnitedHealth Group director reports quarterly equity compensation grant
A UnitedHealth Group director reported receiving 285 shares of common stock on 01/02/2026 at a price of $0, reflecting a grant of deferred stock units as regular quarterly compensation for Board service. After this grant, the director beneficially owns 10,160 shares directly and 6,033 shares indirectly through a trust. The deferred stock units are immediately vested but must be held until the director’s service on the Board is completed.
UnitedHealth Group reported an insider equity transaction involving one of its directors. On 01/02/2026, the director received 168 shares of common stock, described as a regular quarterly compensation grant for board service. The shares were acquired at a stated price of $0, reflecting that they are part of non-cash director compensation rather than an open-market purchase.
Following this grant, the director beneficially owns 2,075 shares of UnitedHealth Group common stock directly and 3,800 shares indirectly through a trust. The filing records the transaction as an acquisition of common stock and confirms it is being reported by a single reporting person.
UnitedHealth Group director reports quarterly equity compensation. Director John H. Noseworthy M.D., a board member of UnitedHealth Group Inc., reported receiving 261 shares of common stock on 01/02/2026 at a stated price of
According to the disclosure, these are deferred stock units granted as regular quarterly compensation for service as a director. The units are immediately vested but must be held until the director’s service on the Board is completed. After this grant, the director beneficially owns 6,997 shares directly.
UnitedHealth Group director reports quarterly equity grant
A director of UnitedHealth Group received 279 deferred stock units of common stock on 01/02/2026 as regular quarterly compensation for Board service. These deferred stock units vest immediately but must be held until the director’s service on the Board is completed. Following this grant, the director beneficially owns a total of 7,219 shares or units of UnitedHealth Group common stock, held directly.
UnitedHealth Group director reports quarterly deferred stock grant
A UnitedHealth Group director reported receiving 125 deferred stock units of common stock on January 2, 2026 as regular quarterly compensation for Board service. The filing states these deferred stock units are immediately vested but must be held until the director completes service on the Board. After this grant, the director beneficially owns 125 shares in direct form.
UnitedHealth Group director Michele J. Hooper reported receiving 168 deferred stock units of UnitedHealth Group common stock on 01/02/2026 as regular quarterly compensation for service on the Board. These deferred stock units were granted at a price of $0, are immediately vested, and must be retained until she completes her service as a director. Following this grant, she beneficially owns 41,294 shares of UnitedHealth Group common stock in direct ownership.
UnitedHealth Group director reports quarterly stock compensation. Director Frederick William McNabb III received 316 deferred stock units of UnitedHealth Group common stock on 01/02/2026 at a price of $0, reflecting regular quarterly compensation for board service. Following this grant, he beneficially owns 14,710 shares/units of common stock.
The filing explains that these deferred stock units are immediately vested but must be held until the director completes service on the Board. The report is filed as a Form 4 by a single reporting person and reflects a routine equity-based compensation award for a non-employee director.
UnitedHealth Group Inc. director Charles D. Baker reported a routine equity compensation transaction. On 01/02/2026, he acquired 279 deferred stock units of UnitedHealth Group common stock at a price of $0 per unit. These deferred stock units are granted as regular quarterly compensation for service as a director and are immediately vested, but must be retained until he completes his service on the Board. Following this grant, he beneficially owns 1,806 shares/deferred stock units on a direct basis.
FAQ
What is the current stock price of Unitedhealth Gp (UNH)?
What is the market cap of Unitedhealth Gp (UNH)?
